Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL
07 avr. 2020 07h00 HE
|
Precision Biosciences
PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic FDA has authorized Precision to begin dosing with PBCAR20A at Dose Level 2 DURHAM,...
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate
09 déc. 2019 07h00 HE
|
Precision Biosciences
-PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%)...
Autolus Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
13 nov. 2019 16h02 HE
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
06 nov. 2019 09h01 HE
|
Precision Biosciences
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- ...
Autolus Therapeutics to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7
31 oct. 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03 oct. 2019 09h08 HE
|
Autolus Therapeutics plc
LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
07 mai 2019 16h05 HE
|
Autolus Therapeutics plc
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Pricing of Public Offering
10 avr. 2019 21h19 HE
|
Autolus Therapeutics plc
LONDON, April 10, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
08 avr. 2019 16h40 HE
|
Autolus Therapeutics plc
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
01 avr. 2019 13h05 HE
|
Autolus Therapeutics plc
Initial results from the trial show 88% molecular complete response at one month with well-tolerated safety profile Management to Hold Conference Call on April 2, 2019 at 8:00am ET / 1:00pm BST ...